Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The only financial figures disclosed are the share prices used for notional re-investment on April 13, 2010:
- Ordinary shares: £12.74 per share
- Ordinary Share ADRs: $38.86 per ADR
Material Changes
The filing reports an increase in the notional interests of specific individuals in Ordinary shares and ADRs. This change resulted from the notional re-investment of the dividend paid to shareholders on April 8, 2010. No material changes to the company's operational or financial status are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- The specific list of directors and managers whose notional shareholdings increased.
- The exact number of Ordinary shares and ADRs added to each participant's notional interest.
- The vesting schedule and conditions for the Performance Share Plan to determine when these notional holdings convert to actual payouts.
- The dividend payment date of April 8, 2010, which triggered the re-investment.